Recent reports from the results of the PROFILE study document the superiority of Crizotinib treatment in NSCLC patients with ALK genetic abnormalities compared with standard second line chemotherapy (Shaw et al. 2013;Pilotto et al. 2013). Here, ALK is linked to non-small cell lung carcinoma.